1.0Pharmacology/pharmBradley Olson/pharm/author/bradley-olson/rich600338<blockquote class="wp-embedded-content" data-secret="MLbYSC9vZQ"><a href="/pharm/directory/rudolph-l-juliano-phd/">Rudolph L. Juliano, PhD</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/pharm/directory/rudolph-l-juliano-phd/embed/#?secret=MLbYSC9vZQ" width="600" height="338" title="“Rudolph L. Juliano, PhD” — Pharmacology" data-secret="MLbYSC9vZQ" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> /pharm/wp-content/uploads/sites/930/2018/11/dr-rudy-juliano-named-cary-c-boshamer-distinguished-professor-image2.jpeg115147Research Interests Oligonucleotide-based therapeutics Development of small molecules to enhance oligonucleotide therapeutics Intracellular trafficking of antisense and siRNA oligonucleotides in cancer cells Research Synopsis Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides A key impediment to oligonucleotide-based therapeutics is the difficulty in delivering these large, highly polar molecules to … Read more